Catalent Expert Conducts Workshop On Solid Dosage Forms
Somerset, NJ, June 11, 2012 — Michael Valazza, Vice President in Catalent’s Modified Release Technologies business will conduct a workshop on “Coordination of Activities and Responsibilities for Solid Dosage Forms” at the Pharmaceutical Technology Transfer Course being held in Amsterdam, The Netherlands on June 13-14, 2012.
The course will provide a basic understanding of the technology transfer of analytical methods, quality control standards, packaging components/operations and various pharmaceutical dosage forms from R&D to manufacturing.
Catalent is a world leader in drug delivery solutions with a proven track record of helping customers create better treatments by boosting bioavailability, solubility, and permeability; improving ease and route of administration; and increasing patient compliance. Catalent’s unique drug delivery technologies include softgels and Vegicaps® capsules and controlled release technologies, such as OptiMeltTM hot melt extrusion, OSDrC® OptiDoseTM optimized dosing, and Zydis® fast-dissolve tablets, to help get more molecules to market faster and enhance product performance.
Michael Valazza is currently Vice President of Global Business Development specializing in Modified Release Technology and other differentiated oral Pharmaceutical dosage forms for Catalent Pharma Solutions, a position he has held since 2007. Mr. Valazza has over 30 years of experience in the pharmaceutical industry, having worked previously for Glatt Air Techniques and Schering Pharmaceuticals. Mr. Valazza is a registered pharmacist, a member of a variety of professional organizations including the American Association of Pharmaceutical Scientists and the Controlled Release Society, and has published articles in various scientific journals. He has also made presentations at many conferences on subjects relating to outsourcing, technology transfer and fluid bed processing. Mr. Valazza attended Rutgers University where he received a B.S. in Pharmacy in 1982.
For more information on this course, please click on this link: www.cfpa.com//courseSummary.aspx
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,400 people at 29 facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ.
more products. better treatments. reliably supplied.™
Zydis® is a registered trademark of Catalent Pharma Solutions, Inc.
OptiDose TM and OptiMelt TM are trademarks of Catalent Pharma Solutions, Inc.
OSDrC® is a registered trademark of Sanwa Kagaku Kenyusho Co.